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Summary 37 
Hepatocellular carcinoma, the most common type of liver malignancy, is one of 38 
the most lethal forms of cancer. We identified a long non-coding RNA, Gm19705, that is 39 
over-expressed in hepatocellular carcinoma and mouse embryonic stem cells. We 40 
named this RNA Pluripotency and Hepatocyte Associated RNA Overexpressed in HCC, 41 
or PHAROH. Depletion of PHAROH impacts cell proliferation and migration, which can 42 
be rescued by ectopic expression of PHAROH. RNA-seq analysis of PHAROH 43 
knockouts revealed that a large number of genes with decreased expression contain a 44 
Myc motif in their promoter. MYC is decreased at the protein level, but not the mRNA 45 
level. RNA-antisense pulldown identified nucleolysin TIAR, a translational repressor, to 46 
bind to a 71-nt hairpin within PHAROH, sequestration of which increases MYC 47 
translation. In summary, our data suggest that PHAROH regulates MYC translation by 48 
sequestering TIAR and as such represents a potentially exciting diagnostic or 49 
therapeutic target in hepatocellular carcinoma. 50 
  51 
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Introduction 52 
Hepatocellular carcinoma (HCC), the most common type of liver malignancy, is 53 
one of the most lethal forms of cancer (Asrani et al., 2019). HCC is the fifth-most 54 
frequently diagnosed cancer and the third-leading cause of cancer-related deaths 55 
worldwide (Villanueva, 2019). The molecular landscape of HCC is very complex and 56 
includes multiple genetic and epigenetic modifications which could represent new 57 
diagnosis and therapeutic targets. In this sense, multiple studies have established 58 
molecular classifications of HCC subtypes that could be related to clinical management 59 
and outcomes (Dhanasekaran et al., 2019; Llovet et al., 2018). For instance, Hoshida et 60 
al. classified HCC into S1, S2, and S3  subtypes by means of their histological, 61 
pathological, and molecular signatures (Hoshida et al., 2009). S1 tumors exhibit high 62 
TGF-β and Wnt signaling activity but do not harbor mutations or genomic changes. The 63 
tumors are relatively large, poorly-differentiated, and associated with poor survival. S2 64 
tumors have increased levels of Myc and phospho-Akt and overexpress α-fetoprotein, 65 
an HCC serum biomarker. S3 tumors harbor mutations in CTNNB1 (β-catenin) but tend 66 
to be well-differentiated and are associated with good overall survival. 67 
The standard of care for advanced HCC is treatment with sorafenib, a multi-68 
kinase inhibitor that targets Raf, receptor tyrosine kinases (RTKs), and the platelet-69 
derived growth factor receptor (PDGFR). Sorafenib extends the median survival time 70 
from 7.9 months to 10.7 months, and lenvatinib, a multiple VEGFR kinase inhibitor, has 71 
been reported to extend survival to 13.6 months (Llovet et al., 2018; Philip et al., 2005; 72 
Rimassa & Santoro, 2009). Combination therapies of VEGF antagonists together with 73 
sorafenib or erlontinib are currently being tested (Dhanasekaran et al., 2019; Greten et 74 
al., 2019; Quintela-Fandino et al., 2010). However, even with the most advanced forms 75 
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of treatment, the global death toll per year reaches 700,000, creating a mortality ratio of 76 
1.07 with a 5-year survival rate of 18% (Ferlay et al., 2010; Siegel et al., 2014; 77 
Villanueva, 2019). Not only is it difficult to diagnose HCC in the early stages, but there is 78 
also a poor response to the currently available treatments. Thus, novel therapeutic 79 
targets and treatments for HCC are urgently needed. 80 
The ENCODE consortium revealed that as much as 80% of the human genome 81 
can be transcribed, while only 2% of the genome encodes for proteins (Djebali et al., 82 
2012). Thousands of transcripts from 200 nucleotides (nt) to over one-hundred 83 
kilobases (kb) in length, called long non-coding RNAs (lncRNAs), are the largest and 84 
most diverse class of non-protein-coding transcripts. They commonly originate from 85 
intergenic regions or introns and can be transcribed in the sense or anti-sense direction. 86 
Most are produced by RNA polymerase II and can be capped, spliced and poly-87 
adenylated (reviewed in Rinn & Chang, 2012). Strikingly, many are expressed in a cell 88 
or tissue-specific manner and undergo changes in expression level during cellular 89 
differentiation and in cancers (Costa, 2005; Dinger et al., 2008). These lncRNAs present 90 
as an exciting class of regulatory molecules to pursue, as some are dysregulated in 91 
HCC and have potential to be specific to a subtype of HCC (Li et al., 2015).  92 
One of the few examples of a lncRNA that has been studied in the context of 93 
HCC is the homeobox (HOX) anti-sense intergenic RNA (HOTAIR). This transcript acts 94 
in trans by recruiting the Polycomb repressive complex 2 (PRC2), the lysine-specific 95 
histone demethylase (LSD1) and the CoREST/REST H3K4 demethylase complex to 96 
their target genes (Ezponda & Licht, 2014). HOTAIR promotes HCC cell migration and 97 
invasion by repressing RNA binding motif protein 38 (RBM38), which is otherwise 98 
targeted by p53 to induce cell cycle arrest in G1 (Shu et al., 2006; Yu et al., 2015). 99 
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Another mechanism through which lncRNAs function involves inhibitory sequestration of 100 
miRNAs and transcription factors (Cesana et al., 2011). In HCC, the lncRNA HULC 101 
(highly upregulated in liver cancer) sequesters miR-372, which represses the protein 102 
kinase PRKACB, and down-regulates the tumor suppressor gene CDKN2C (p18) (J. 103 
Wang et al., 2010). Similarly, the highly-conserved MALAT1 lncRNA controls 104 
expression of a set of genes associated with cell proliferation and migration and is 105 
upregulated in many solid carcinomas (Amodio et al., 2018; R. Lin et al., 2007); siRNA 106 
knockdown of MALAT1 in HCC cell lines decreases cell proliferation, migration, and 107 
invasion (Lai et al., 2012). 108 
Only a small number of the thousands of lncRNAs have been characterized in 109 
regard to HCC. Therefore, whether and how additional lncRNAs contribute to HCC 110 
remains unknown, and it is not fully understood how lncRNAs acquire specificity in their 111 
mode of action at individual gene loci. A lack of targetable molecules limits the 112 
effectiveness of treatments for HCC, and this class of regulatory RNAs has great 113 
potential to provide novel therapeutic targets.  114 
 Here, we reanalyzed naïve and differentiated transcriptomes of mouse 115 
embryonic stem cells (ESCs) in the context of the GENCODE M20 annotation. We 116 
aimed to identify lncRNAs that are required for the pluripotency gene expression 117 
program, and dysregulated in cancer, with a specific focus on HCC. Since normal 118 
development and differentiation are tightly regulated, dysfunction of potential regulatory 119 
RNAs may lead to various disease phenotypes including cancer. One lncRNA that is 120 
highly upregulated in HCC is of special interest, and we show that it interacts with and 121 
sequesters the translation repressor nucleolysin TIAR resulting in an increase of Myc 122 
translation. Together, our findings identified a mechanism by which a lncRNA regulates 123 
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translation of MYC in HCC by sequestering a translation inhibitor and as such has 124 
potential as a therapeutic target in HCC. 125 
Results 126 
Deep sequencing identifies 40 long non-coding RNAs dysregulated in embryonic stem 127 
cells and cancer 128 
Since normal development and differentiation are tightly regulated processes, we 129 
reasoned that lncRNAs whose expressions are ESC specific and can be found to also 130 
exhibit altered expression in cancer, may have important potential roles in regulating 131 
critical cellular processes. 132 
We re-analyzed the raw data from our published differential RNA-seq screen 133 
comparing lncRNA expression in mouse ESCs vs neural progenitor cells (NPCs) 134 
(Bergmann et al., 2015), using updated bioinformatic tools and the recently released 135 
GENCODE M20 annotation (January 2019), which has nearly 2.5 times more annotated 136 
lncRNAs than the previously used GENCODE M3. Principal component analysis (PCA) 137 
of the processed data showed that ESCs and NPCs independently cluster, and the 138 
difference between ESC cell lines (AB2.2) and mouse derived ESCs only accounted for 139 
4% of the variance (Figure 1A). Additionally, we prioritized transcripts with an FPKM 140 
value greater than 1, and those that were more than 2-fold upregulated in ESCs 141 
compared to NPCs. This left us with 147 ESC specific transcripts. Since our goal is to 142 
discover novel transcripts that may play a role in the progression of human cancer, we 143 
first needed to identify the human homologues of the 147 mouse ESC transcripts. In 144 
addition to sequence conservation, we also evaluated syntenic conservation of the 145 
mouse lncRNAs to the human genome, due to the fact that many lncRNAs are not 146 
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conserved on the sequence level. Finally, we queried TCGA databases via cBioportal, 147 
to find lncRNAs that were altered in cancer (Figure 1B). A final candidate list of 40 148 
lncRNAs that are enriched in ESCs, and dysregulated in cancer, was identified (Table 149 
1). Our candidate list contains lncRNAs that have a wide range of expression, and also 150 
contains several previously identified lncRNAs that have been found to be dysregulated 151 
in cancer (NEAT1, FIRRE, XIST, DANCR, and GAS5), verifying the validity of the 152 
approach (Figure 1–figure supplement 1A) (Ji et al., 2019; Soudyab et al., 2016; Yuan 153 
et al., 2016). 154 
We analyzed the ENCODE expression datasets of adult mouse tissue to 155 
compare the expression levels of the candidates across tissues (Figure 1C). LncRNAs 156 
are known to have distinct expression patterns across different tissues, and our results 157 
support the notion that lncRNAs are generally not pan-expressed. Interestingly, many of 158 
the identified lncRNAs are enriched in embryonic liver, which is the organ with the most 159 
regenerative capacity, yet never grows past its original size. 160 
From here, we decided to focus on liver enriched candidate mouse lncRNAs, 161 
especially those that were primarily dysregulated in liver cancers. Because HCC is one 162 
of the deadliest cancers and has inadequate treatment options, we focused on lncRNAs 163 
that were dysregulated in HCC, LINC00862, TSPOAP-AS1, MIR17HG, and SNHG5, 164 
with their mouse counterparts being Gm19705, Mir142hg, Mir17hg, and Snhg5, 165 
respectively. Out of these four lncRNAs that were detected to be amplified in HCC, 166 
LINC00862 was the highest at 13% of all liver cancer cases (Figure 1–figure 167 
supplement 1B). We assayed LINC00862 expression in human samples obtained from 168 
healthy and cirrhotic livers and HCC nodules. Indeed, we found that levels of 169 
LINC00862 were elevated in HCC tumor nodules, but also in cirrhotic liver, suggesting 170 
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that it may play a role in HCC progression (Figure 1D). In addition, we also assayed 171 
LINC00862 expression in human HCC cell lines and we found it to be upregulated in 172 
numerous HCC cell lines compared to the normal human liver cell line, THLE-2 (Figure 173 
1E). 174 
 In order to use a more tractable model system, we assessed the conservation of 175 
LINC00862 and its potential mouse counterpart, GM19705, which was internally 176 
designated as lnc05 in previous analyses (Bergmann et al., 2015). While much shorter, 177 
GM19705 has 51% sequence identity and the gene order is syntenically conserved, 178 
although a reversal event most likely occurred within the locus (Figure 1–figure 179 
supplement 1C). Weighted gene correlation network analysis of GM19705 identified that 180 
its expression is highly correlated with those of cell cycle genes, such as BRCA1 and 181 
BRCA2 (Figure 1–figure supplement 1D). GO-term analysis of the cluster identified cell 182 
cycle processes as highly enriched, indicating that GM19705 may play a role in the 183 
regulation of the cell cycle (Figure 1–figure supplement 1E). Re-analysis of previously 184 
published single cell analysis of normal adult mouse liver (Tabula Muris et al., 2018) 185 
identified GM19705 expression to be low overall, as expected, but highly expressed 186 
exclusively in a subset of hepatocytes (Figure 1–figure supplement 1F).  187 
 Our analysis identified GM19705/LINC00862 as a lncRNA that is expressed in 188 
ESCs and dysregulated in HCC. We found that GM19705 is also highly expressed in 189 
developing liver and exclusively in adult hepatocytes, and it may have a potential 190 
function to regulate the cell cycle. Therefore, we named this mouse lncRNA – 191 
Pluripotency and Hepatocyte Associated RNA Overexpressed in HCC, or PHAROH. 192 
 193 
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PHAROH is a novel lncRNA that is highly expressed in embryonic liver and mouse 194 
hepatocellular carcinoma 195 
 PHAROH is an intergenic lncRNA located on mouse chr1:1qE4. 5’ and 3’ rapid 196 
extension of cDNA ends (RACE) revealed the presence of two isoforms that share two 197 
common exons and are both ~450 nt (Figure 2A). In silico analysis of the coding 198 
potential by three independent algorithms, which use codon bias (CPAT/CPC) and 199 
comparative genomics (PhyloCSF), all point towards the low coding potential score of 200 
PHAROH, compared to the Gapdh control (Figure 2–figure supplement 2A-B). From 201 
here on, only qPCR primers that amplify common exons were used. We confirmed 202 
expression levels of PHAROH in developing liver by assaying the liver bud from E14 203 
and E18 embryos and found that they were 7-9 fold enriched compared to adult liver 204 
(Figure 2B). Because the liver is one of the main sites of hematopoiesis in the embryo, 205 
we measured PHAROH levels in embryonic blood and found that expression was 206 
exclusive to the liver, and not to hematopoietic cells (Figure 2–figure supplement 2C). 207 
PHAROH was also found to be upregulated in a partial hepatectomy model of liver 208 
regeneration (Figure 2–figure supplement 2D), where the expression was correlated 209 
with time points of concerted DNA synthesis, but did not fluctuate across the cell cycle 210 
(Figure 2–figure supplement 2E). To confirm PHAROH’s involvement in HCC, we used 211 
a diethylnitrosamine (DEN) induced carcinogenic model of liver injury. By 11 months 212 
post DEN treatment, we were able to visualize HCC tumor nodules, which had elevated 213 
levels of PHAROH (Figure 2C). In order to facilitate the molecular and biochemical 214 
study of PHAROH, we chose two mouse HCC cell lines, Hepa1-6 and Hepa1c1c7, and 215 
indeed found that PHAROH was 3-4-fold more enriched than in ESCs, and 8-10-fold 216 
increased over the AML12 mouse normal hepatocyte cell line (Figure 2D). 217 
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 Single molecule RNA-FISH revealed that PHAROH is entirely nuclear in ESCs, 218 
with an average of 3-5 foci per cell, whereas it is evenly distributed between the nucleus 219 
and cytoplasm in Hepa1-6 cells, with an average of 25 foci per cell (Figure 2E-F). 220 
Isoform 1 is expressed mostly in ESCs while isoform 2 of PHAROH dominates HCC cell 221 
lines (Figure 2A, Figure 2–figure supplement 2F). Cellular fractionation of Hepa1-6 cells 222 
corroborates the RNA-FISH determined localization of PHAROH as well, which GAPDH 223 
and MALAT1 localized correctly to previously determined cellular fractions (Figure 2G). 224 
Additional lncRNAs tested, such as XIST, FIRRE, and NEAT1, also localized to their 225 
expected cellular fractions (Figure 2–figure supplement 2G). It was also determined that 226 
PHAROH has a relatively longer half-life in the Hepa1-6 cell line (10.8 h), compared to 227 
MALAT1 (8.0 h), and XIST (4.2 h) (Figure 2–figure supplement 2H) (Tani et al., 2012; 228 
Yamada et al., 2015). Taken together, PHAROH is an embryonic stem cell and fetal 229 
liver specific lncRNA, that is upregulated in the context of hepatocellular carcinoma. 230 
 231 
Targeted knockout of PHAROH  232 
 To evaluate the functional role of PHAROH, we generated targeted knockouts 233 
using CRISPR/Cas9 technology. Two sgRNA guides were designed to delete a region 234 
~700 bp upstream of the TSS, and ~100 bp downstream of the TSS. We chose to 235 
transiently express enhanced specificity Cas9 (eSpCas9-1.1) in order to increase 236 
specificity, decrease off-target double stranded breaks, and also to avoid stable 237 
integration of Cas9 endonuclease due to its transformative potential (Slaymaker et al., 238 
2016). In addition to using two guides targeting PHAROH, we used an sgRNA targeting 239 
renilla luciferase as a non-targeting control. Each guide was cloned into a separate 240 
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fluorescent protein vector (GFP or mCherry) to allow for subsequent selection. Cells 241 
were single cell sorted 48h after nucleofection to account for heterogeneity of deletions 242 
among a pooled cell population, which may give certain cells a growth advantage. 85% 243 
of the cells were GFP+/mCherry+, and we selected four clones for subsequent analysis 244 
(Figure 3–figure supplement 3A). All selected clones had the correct homozygous 245 
deletion when assayed by genomic PCR (Figure 3A). qRT-PCR indicated that PHAROH 246 
was knocked down 80-95% (Figure 3B). 247 
 We assayed the proliferative state of the PHAROH knockout clones and found a 248 
decrease in proliferation. The doubling time of the knockout clones increased to 18.2h, 249 
compared to the wildtype doubling time of 14.8h, and ectopic expression of PHAROH 250 
reduced the doubling time to nearly wild-type levels (Figure 3C). Ectopic expression of 251 
PHAROH also successfully rescued the proliferation phenotype in the knockout clones, 252 
suggesting that PHAROH functions in trans (Figure 3D). Migration distance was also 253 
decreased by 50% in the knockout clones (Figure 3E). 254 
 In addition to assessing the role of PHAROH in knockout clones we also  255 
employed the use of antisense oligonucleotides (ASO) to knockdown PHAROH. We 256 
treated cells independently with a control scrambled cEt ASO, or two independent cEt 257 
ASOs complementary to the last exon of PHAROH. ASOs were nucleofected at a 258 
concentration of 2 uM, and we are able to achieve a >90% knockdown at 24h, and a 259 
~50% knockdown was still achieved after 96h (Figure 3–figure supplement 3B). 260 
Proliferation assays using manual cell counts and MTS assay shows a 50% reduction in 261 
proliferation at 4 days (96h), similar to that achieved in our knockout clones, further 262 
supporting a role of PHAROH in cell proliferation (Figure 3–figure supplement 3C). 263 
Addition of the ASO into the medium allowed for the knockdown to persist for longer 264 
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duration to study the impact on clonogenic ability (Figure 3F). Colony formation assays 265 
demonstrated that knockdown of PHAROH significantly inhibits clonogenic growth of 266 
HCC cells in a dose dependent manner (Figure 3G, Figure 3–figure supplement 3D). 267 
 To investigate the global effect of PHAROH depletion, we performed poly(A)+ 268 
RNA-seq on control and knockout clones (Figure 4–figure supplement 4A-B). We 269 
identified 810 differentially expressed genes, and GO term analysis revealed regulation 270 
of cell proliferation, locomotion, and cell motility as the highest enriched terms (Figure 271 
4A). To determine if these differentially expressed genes were predominantly controlled 272 
by common transcription factors, we performed de novo and known motif analysis. 273 
Interestingly, promoter motif analysis of differentially expressed genes revealed 274 
enrichment of the Myc motif in our dataset suggesting a subset of the genes were under 275 
the transcriptional control of Myc (Figure 4–figure supplement 4C). This was intriguing 276 
because Myc is known to regulate cell proliferation, and is highly amplified in nearly half 277 
of hepatocellular carcinomas (Zheng et al., 2017). However, Myc expression changes 278 
were not detected in our RNA-seq analysis, nor was there any statistically significant 279 
change compared to sgRenilla controls when assayed by qRT-PCR (Figure 4B). 280 
Strikingly, MYC protein levels were substantially decreased in all of the PHAROH 281 
knockout clones, as detected by western blot and immunofluorescence, suggesting that 282 
PHAROH regulates Myc post-transcriptionally (Figure 4C, Figure 4–figure supplement 283 
4D-E). qRT-PCR of genes downstream of Myc that were identified through our analysis 284 
were also significantly downregulated in PHAROH knockout clones (Figure 4D). Thus, 285 
we suggest that depletion of PHAROH decreases MYC protein levels, and ultimately 286 
cell proliferation. 287 
 288 
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RAP-MS identifies TIAR as the major interactor of PHAROH 289 
 LncRNAs can act as structural scaffolds to promote interaction between protein 290 
complexes or to sequester a specific protein (Lee et al., 2016; Tsai et al., 2010). 291 
Because modulation of PHAROH levels change Myc protein levels, but not mRNA 292 
levels to a significant degree, we hypothesized that PHAROH may be regulating the 293 
translation of MYC through a protein mediator. In order to search for PHAROH 294 
interacting proteins, we used a pulldown method adapted from the previously published 295 
RNA antisense purification-mass spectrometry (RAP-MS) (McHugh et al., 2015). In lieu 296 
of pooling all available antisense capture biotinylated oligonucleotides (oligos), we 297 
reasoned that individual oligos may be similarly effective, and can be used as powerful 298 
biological replicates. In addition, we would minimize oligo-specific off targets by verifying 299 
our results with multiple oligos. To this end, we screened through five 20-mer 3’ 300 
biotinylated DNA oligos that tiled the length of PHAROH, and found that four out of the 301 
five oligos pulled down >80% of endogenous PHAROH, while the pulldown of a control 302 
RNA, PPIB, remained low. (Figure 5A, Figure 5–figure supplement 5A). 303 
For elution of PHAROH, we tested a range of temperatures and found that the 304 
elution efficiency reaches the maximum at 40° C, and thus we used this temperature for 305 
further experiments (Figure 5B). The remaining level of PHAROH RNA on the beads 306 
was the direct inverse of the eluate (Figure 5–figure supplement 5B). We chose PPIB as 307 
a negative control because it is a housekeeping mRNA that is expressed on the same 308 
order of magnitude as PHAROH, and is not expected to interact with the same proteins. 309 
We screened through ten oligos against PPIB, and found only one that pulled PPIB 310 
down at ~60% efficiency, and eluted at the same temperature as PHAROH (Figure 5–311 
figure supplement 5C-D). Off-target RNA pulldown, such as PHAROH and 18S rRNA, 312 
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remained minimal when using the oligo antisense to PPIB (Figure 5–figure supplement 313 
5C). 314 
 To identify proteins that bind to PHAROH, we analyzed two independent oligos 315 
that target PHAROH, and two replicates of PPIB, on a single 4-plex iTRAQ (isobaric tag 316 
for relative and absolute quantitation) mass spectrometry cassette and identified a total 317 
of 690 proteins. By plotting the log2 enrichment ratio of PHAROH hits divided by PPIB 318 
hits, quadrant I will contain proteins that both oligos against PHAROH recognize, and 319 
quadrant III will be enriched for proteins that bind specifically to PPIB. Quadrant III was 320 
enriched for keratins, elongation factors, and ribosomal proteins. Interestingly, the top 321 
hit in quadrant I is nucleolysin TIAR (TIAL-1), an RNA-binding protein that controls 322 
mRNA translation by binding to AU-rich elements in the 3’ UTR of mRNA (Figure 5C, 323 
Table 2) (Mazan-Mamczarz et al., 2006). TIAR is present in <10% of all experiments 324 
queried on Crapome.org (31/411). Immunoblots for TIAR confirm the mass 325 
spectrometry data in that TIAR is specific to PHAROH pull-down oligos, and also is 326 
eluted at 40° C (Fig 5D). Additional controls that are not complementary to the mouse 327 
genome and oligos targeting PHAROH also confirm the TIAR hit, and it is reproducible 328 
in two independent HCC cell lines (Figure 5E). RNase A treatment of the lysate largely 329 
abolished the interaction, which indicates that the interaction is RNA mediated, and not 330 
the result of direct binding to the oligo (Figure 5E). Immunoprecipitation of TIAR and 331 
subsequent extraction of interacting RNA shows enrichment for PHAROH when 332 
compared to PPIB and IgG control (Figure 5F). Thus, together these data indicate that 333 
TIAR is a bona fide interactor of PHAROH. 334 
 335 
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A 71-nt sequence in PHAROH has four TIAR binding sites 336 
 A previous study on TIAR has mapped its RNA recognition motif across the 337 
transcriptome (Meyer et al., 2018). Analysis of PHAROH’s sequence reveals that TIAR 338 
binding sites are enriched in the 5’ end of the transcript of both isoforms (Figure 6A). To 339 
determine if there are any conserved structure within PHAROH that mediates this 340 
interaction, RNA folding prediction algorithms, mFold and RNAfold, were used. The two 341 
strongest TIAR binding sequences (TTTT and ATTT/TTTA) were mapped onto ten 342 
outputted predicted structures (Figure 6–figure supplement 6A). Strikingly, four out of 343 
the seven binding sites consistently mapped to a hairpin that was conserved throughout 344 
all predicted structures. Three of the strongest binding motifs localize to the stem of the 345 
hairpin, while one secondary motif resides in a bulge (Figure 6B). These data indicate 346 
that the sequence is a highly concentrated site for TIAR binding, and is designed to 347 
potentially sequester multiple copies of TIAR. 348 
RNA electromobility shift assay (EMSA) of the hairpin and recombinant human 349 
TIAR showed that as TIAR concentration increases, it binds to the PHAROH hairpin 350 
multiple times (Figure 6C). TIAR has a preference to bind two and four times, rather 351 
than once or three times. Densitometry quantification of the remaining free probe shows 352 
that TIAR has an approximate dissociation constant of 2 nM, consistent with the 353 
literature (Kim et al., 2011) (Figure 6–figure supplement 6B). Addition of an antibody 354 
against TIAR creates a supershift, showing that the interaction is specific, while addition 355 
of IgG does not. The interaction can be abolished with addition of 20x unlabeled probe 356 
as well (Figure 6E, left panel). 357 
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 To determine if binding of TIAR is specific to the sequence and mapped motifs, 358 
we created sequential mutations of the hairpin by changing the non-canonical Watson-359 
Crick base pairs (starred and in red) to canonical ones (Figure 6B). Mutation of the first 360 
binding site (m1) slightly reduced specificity of TIAR to the hairpin, but changes the 361 
preference of TIAR binding to one and two units (Figure 6E, right panel). Mutation of m2 362 
greatly reduced TIAR association, and only two bands are highly visible (Figure 6E, 363 
right panel). However, mutation of three binding sites (m3) did not appreciably change 364 
the pattern, as compared to m2, perhaps suggesting that the weaker binding site is only 365 
used cooperatively (Figure 6–figure supplement 6C). Mutation of all four binding sites 366 
(m4) showed minimal TIAR binding (Figure 6E). Taken together, these data indicate 367 
that TIAR binds directly to the 71-nt sequence on PHAROH, which can fold into a 368 
hairpin, and preferentially binds two or four times. 369 
 370 
PHAROH modulates Myc translation by sequestering TIAR 371 
 TIAR has been shown to bind to the 3’ UTR of mRNAs containing AU-rich 372 
elements in order to inhibit their translation (Mazan-Mamczarz et al., 2006). It has also 373 
been shown that TIAR binds to the 3’ UTR of Myc mRNA (Liao et al., 2007). Our data 374 
suggests that PHAROH serves to competitively sequester TIAR in order to allow for 375 
increased MYC translation. Thus, knockout or knockdown of PHAROH will free 376 
additional TIAR molecules to bind to the 3’ UTR of Myc and inhibit its translation. 377 
 We began by determining where TIAR binds to Myc mRNA. Mapping PAR-CLIP 378 
reads from (Meyer et al., 2018) shows two distinct binding sequences on the human 379 
MYC mRNA, but only one sequence maps to the mouse genome. The stretch of 53-nt 380 
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sequence has three distinct regions that are enriched in poly-uridines, but structural 381 
prediction largely places the sequences in a loop formation (Figure 7–figure supplement 382 
7A-B). RNA EMSA of the 53-nt 3’ UTR and recombinant TIAR showed preference for a 383 
singular binding event, and three events are only seen when the binding reaction is 384 
saturated by TIAR (Figure 7A). ASO mediated knockdown of PHAROH shows reduction 385 
of MYC protein similar to the knockouts, but no change in mRNA levels, or TIAR protein 386 
levels (Figure 7B, Figure 7–figure supplement 7C). While mRNAs are generally much 387 
more highly expressed than lncRNAs, Myc is only 3-fold more expressed than PHAROH 388 
in HCC cell lines (Figure 7B). In addition, there are multiple TIAR binding sites on 389 
PHAROH, which increases the feasibility of a competition model (Figure 7B). 390 
 Next, we tested this hypothesis in vitro, by allowing TIAR to bind to the 53-nt Myc 391 
3’ UTR, and titrating increasing amounts of PHAROH or the mutant PHAROH transcript. 392 
The wildtype PHAROH hairpin can be seen to compete with Myc very effectively at 393 
nearly all tested ratios, with near complete competition at 10:1 ratio (Figure 7C). 394 
However, the fully mutant PHAROH was not able to compete with Myc nearly as 395 
effectively, and was only seen to be slightly effective at the 10:1 ratio (Figure 7C). This 396 
data suggests that the PHAROH has the capability to successfully compete with the 397 
Myc 3’ UTR binding site in a sequence dependent manner. 398 
 In addition, we cloned the full length Myc 3’UTR into a dual luciferase reporter 399 
construct in order to test our hypothesis in cells. We found that addition of PHAROH 400 
does indeed increase the luciferase signal by ~50% in a dose dependent manner while 401 
the mutant PHAROH did not (Figure 7D, Figure 7–figure supplement 7D). 402 
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 Given that the knockdown or knockout of PHAROH reduces MYC levels due to 403 
the release of TIAR, we asked whether MYC protein levels would change in the context 404 
of PHAROH overexpression. Compared to GFP transfection, overexpression of 405 
PHAROH increases MYC protein levels; however, overexpression of mutant PHAROH 406 
did not change the protein levels of MYC (Figure 7E). Modulation of PHAROH or TIAR 407 
levels did not have an effect on Myc mRNA levels (Figure 7–figure supplement 7E). 408 
 409 
Discussion 410 
 Studies of the transcriptome have shed important insights into the potential role 411 
of the non-coding RNA portion of the genome in basic biology as well as disease. As 412 
such, lncRNAs can serve as biomarkers, tumor suppressors, or oncogenes, and have 413 
great potential as therapeutic targets (reviewed in Arun et al., 2018). Here, we identified 414 
a lncRNA, PHAROH, that is upregulated in mouse ESCs, embryonic and regenerating 415 
adult liver and in HCC. It also has a conserved human ortholog, which is upregulated in 416 
human patient samples from cirrhotic liver and HCC. Genetic knockout or ASO 417 
knockdown of PHAROH  results in a reduction of cell proliferation, migration, and colony 418 
formation. 419 
To elucidate the molecular mechanism through which PHAROH acts in 420 
proliferation, we used RNA-seq and mass spectrometry to provide evidence that 421 
PHAROH regulates MYC translation via sequestering the translational repressor TIAR 422 
in trans. Modulation of PHAROH levels reveal that it is positively correlated with MYC 423 
protein level, which is well known to be associated with HCC and is amplified in nearly 424 
50% of HCC tumors (Peng et al., 1993). In addition, MYC has been characterized as a 425 
 19 
critical player in liver regeneration (Zheng et al., 2017). We identified TIAR as an 426 
intermediate player in the PHAROH-MYC axis, which has been reported to bind to the 3’ 427 
UTR of MYC mRNA and suppress its translation (Mazan-Mamczarz et al., 2006). While 428 
TIAR is an RNA-binding protein that is known for its role in stress granules (Kedersha et 429 
al., 1999), we do not detect stress granule formation in our HCC cell lines as assayed 430 
by immunofluorescence for TIAR (Figure 7–figure supplement 7F). As such, the role of 431 
PHAROH-TIAR lies outside the context of stress granule function. Interestingly, 432 
overexpression of TIAR is a negative prognostic marker for HCC survival (Figure 7–433 
figure supplement 7G) (Uhlen et al., 2017). As the primary mutation of HCC is 434 
commonly amplification of MYC, it is possible that TIAR is upregulated in an attempt to 435 
curb MYC expression. 436 
 Our analysis maps the PHAROH-TIAR interaction to predominantly occur at a 437 
71-nt hairpin at the 5’ end of PHAROH. While PHAROH has two main isoforms that are 438 
selectively expressed in ESCs and HCC, the hairpin is commonly expressed in both 439 
isoforms. TIAR has been classified as an ARE binding protein that recognizes U-rich 440 
and AU-rich sequences. Kinetic and affinity studies have found that TIAR has a 441 
dissociation constant of ~1 nM for U-rich sequences, and ~14 uM for AU-rich 442 
sequences (Kim et al., 2011). One question that is apparent in the RNA-binding protein 443 
field is how RBPs acquire their specificity. While there have been studies that analyze 444 
target RNA structure or RNA recognition motif structure, why RBPs bind one transcript 445 
over another with a similar sequence is still an open question. For example, the 3’ UTR 446 
of Myc contains multiple U-rich stretches, ranging from 3 to 9 resides. It has been 447 
reported that TIAR binds efficiently to uridylate residues of 3-11 length, yet PAR-CLIP 448 
data only reveals two binding events in the human MYC transcript (Kim et al., 2011). In 449 
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addition, the 53-nt fragment that was assayed in this study contained potentially six 450 
TIAR binding sites, yet RNA EMSA analysis revealed a preference for a single binding 451 
event (Figure 7A). One explanation is that PHAROH’s hairpin has uniquely spaced 452 
TIAR binding sites. Because the absolute affinity of TIAR to U-rich sequences is 453 
relatively high, one molecule may sterically block additional binding events. However, if 454 
the binding sites are properly spaced, binding events will be ordered and perhaps even 455 
cooperative. The average gap between binding sites in the Myc fragment is 2 nt, while it 456 
is 10 nt in the PHAROH hairpin, which allows more flexibility in spacing between each 457 
bound protein. 458 
 In addition, one aspect that was not explored was the requirement for the 459 
formation of the hairpin for TIAR binding. Previous studies used synthesized linear 460 
oligos as substrates to test the kinetics of these RBPs, and we also mutated the hairpin 461 
in a way such that structure is preserved. TIAR contains three RNA recognition motifs 462 
(RRM), which typically recognizes single stranded RNA. Therefore, binding of TIAR to 463 
the 71-nt sequence of PHAROH would require unwinding of the potential hairpin, which 464 
is energetically unfavorable. It is also known that TIAR’s RRM2 mainly mediates ssRNA 465 
polyU-binding, but its dsRNA binding capabilities have not been explored (Kim et al., 466 
2013). There are examples where multiple RRMs in tandem can allow for higher RNA 467 
binding affinity and possibly sandwiching dsRNA, and thus it would be possible  that 468 
TIAR binding to the multiple sites on the PHAROH hairpin is cooperative (Allain et al., 469 
2000). 470 
While TIAR may be PHAROH’s top interacting protein, it is unknown whether 471 
PHAROH is TIAR’s highest interacting RNA. This would depend on the relative 472 
abundances of each RNA species that has the potential to bind TIAR, and TIAR’s 473 
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expression level. This seems to be cell type specific, as TIAR was initially studied in 474 
immune cells and was shown to predominantly translationally repress Tnf-α through 475 
binding of the AU-rich sequence in the 3’ UTR (Piecyk et al., 2000). In our cell lines, 476 
Tnf-α is not expressed. Conversely, a screen for proteins that bind to the Tnf-α 3’ UTR 477 
may not necessarily indicate TIAR as a binder, as evidenced by a recent study (Ma & 478 
Mayr, 2018). Another recent study had shown that lncRNA MT1JP functions as a tumor 479 
suppressor and had the capability to bind to TIAR, which suppresses the translation of 480 
p53 (Liu et al., 2016). However, MT1JP is largely cytoplasmic, while TIAR in our context 481 
is mainly nuclear. Thus, while TIAR may bind additional mRNAs or lncRNAs, it seems 482 
that one of the main targets in HCC cell lines is Myc, as supported by statistically 483 
significant promoter enrichment of the downstream targets. 484 
In summary, we have identified a lncRNA, PHAROH, that is enriched in ESCs 485 
and dysregulated in HCC, and found that it acts to sequester TIAR through a hairpin 486 
structure in order to regulate MYC translation. Additionally, based on synteny and 487 
upregulation in human HCC samples, we identified LINC00862 as the possible human 488 
ortholog of PHAROH (Figure 1D).  Future studies will reveal the therapeutic potential of 489 
targeting PHAROH to impact liver development/regeneration and HCC.  490 
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Experimental procedures 491 
Cell culture and genomic PCR 492 
All cell culture reagents were obtained from Gibco (Life Technologies), unless 493 
stated otherwise. Hepa1-6, Hepa1c1c7, AML12, SNU-182, THLE-2 cells were obtained 494 
from ATCC. Huh7, SNU-387, Hep3B, and HepG2 were generous gifts from Scott Lowe 495 
(MSKCC). Hepa1-6, Hepa1c1c7, Huh7, Hep3B, and HepG2 were maintained in DMEM 496 
supplemented with 10% FBS and 1% penicillin/streptomycin. SNU-182 and SNU-387 497 
were maintained in RPMI supplemented with 10% FBS and 1% penicillin/streptomycin. 498 
AML12 was maintained in DMEM:F12 Medium supplemented with 10% fetal bovine 499 
serum, 10 µg/ml insulin, 5.5 µg/ml transferrin, 5 ng/ml selenium, and 40 ng/ml 500 
dexamethasone. THLE-2 cells were maintained in BEGM (BEGM Bullet Kit; CC3170) 501 
where gentamycin/amphotericin and epinephrine were discarded, and extra 5 ng/mL 502 
EGF, 70 ng/mL phosphoethanolamine and 10% fetal bovine serum were added in 503 
addition to the supplied additives. ESCs and NPCs were cultured as in (Bergmann et al., 504 
2015). All cells were cultured in a humidified incubator at 37° C and 5% CO2. Half-life of 505 
RNA was determined by adding α-amanitin to a final concentration of 5 µg/mL. Genomic 506 
DNA was isolated using DNeasy Blood & Tissue (Qiagen). All cell lines were tested for 507 
mycoplasma regularly. 508 
Cellular Fractionation 509 
 Cellular fractionation was performed according to 510 
(https://link.springer.com/protocol/10.1007%2F978-1-4939-4035-6_1). In brief, cells 511 
were collected and resuspended in NP-40 lysis buffer. The cell suspension is overlaid 512 
on top of a sucrose buffer and centrifuged at 3,500 x g for 10 minutes to pellet the nuclei. 513 
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The supernatant (cytoplasm) is collected and the nuclei are resuspended in glycerol 514 
buffer and urea buffer is added to separate the nucleoplasm and chromatin. The cells 515 
are centrifuged at 14,000 x g for 2 minutes and the supernatant (nucleoplasm) is 516 
collected, while the chromatin-RNA is pelleted. 517 
DEN administration 518 
Mice were injected intraperitoneally with diethylnitrosamine (DEN) at 14 days of 519 
age as described (Garcia-Irigoyen et al., 2015). DEN-treated mice, and the 520 
corresponding controls injected with saline, were sacrificed at 5, 8, and 11 months post 521 
injection. 522 
Partial hepatectomy 523 
Two-thirds partial hepatectomy (PH) and control sham operations (SH) were 524 
performed as reported (Berasain et al., 2005). Two SH and four PH mice were 525 
sacrificed at 3, 6, 24, 48 and 72 hours after surgery. Animal experimental protocols 526 
were approved (CEEA 062-16) and performed according to the guidelines of the Ethics 527 
Committee for Animal Testing of the University of Navarra. 528 
Human samples 529 
Samples from patients included in the study were provided by the Biobank of the 530 
University of Navarra (CEI 47/2015) and were processed following standard operating 531 
procedures approved by the Ethical and Scientific Committees. Liver samples from 532 
healthy patients were collected from individuals with normal or minimal changes in the 533 
liver at surgery of digestive tumors or from percutaneous liver biopsy performed 534 
because of mild alterations of liver function. Samples for cirrhotic liver and HCC were 535 
obtained from patients undergoing partial hepatectomy and/or liver transplantation. 536 
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The biobank obtained an informed consent and consent to publish from each 537 
patient and codified samples were provided to the researchers. The study protocol 538 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Samples were 539 
processed following standard operating procedures approved by the Ethical and 540 
Scientific Committees. Liver samples from healthy patients were collected from 541 
individuals with normal or minimal changes in the liver at surgery of digestive tumors or 542 
from percutaneous liver biopsy performed because of mild alterations of liver function. 543 
Samples for cirrhotic liver and HCC were obtained from patients undergoing partial 544 
hepatectomy and/or liver transplantation. 545 
Immunoblotting 546 
To determine protein levels in our system, we used 10% SDS-PAGE gels. Gels 547 
were loaded with 1-μg protein per well (Bradford assay). The following antibodies were 548 
used: β-actin (1:15,000; Sigma), c-Myc (1:1000; CST), TIAR (1:1000; Cell Signaling). 549 
IRDye-800CW was used as a fluor for secondary anti-rabbit antibodies, and IRDye-550 
680RD was used for mouse secondary antibodies. Blots were scanned using the Li-Cor 551 
Odyssey Classic. 552 
Immunoprecipitation  553 
For TIAR immunoprecipitation, one 10 cm plate of Hepa1c1c7 cells at 80% 554 
confluence was lysed in 1 mL Pierce IP Lysis Buffer (supplemented with 100 U/mL 555 
SUPERase-IN and 1X Roche protease inhibitor cocktail) and incubated on ice for 10 556 
min. Lysates centrifuged at 13,000xg for 10 minutes. 3 ug of TIAR antibody or rabbit 557 
IgG were incubated with the lysate at 4°C for 1 hour. 16 uL of Protein A magnetic beads 558 
were washed and added to the lysate and incubated for an additional 30 minutes at 4°C. 559 
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50% of beads were resuspended in Laemmli buffer for western blotting and RNA was 560 
isolated from the remaining beads using TRIzol.  561 
Immunofluorescence staining 562 
#1.5 round glass coverslips were prepared by acid-cleaning prior to seeding cells. 563 
Staining was performed as published previously (Spector, D.L. and H.C. Smith. 1986. 564 
Exp. Cell Res. 163, 87-94). In brief, cells were fixed in 2% PFA for 15 min, washed with 565 
PBS, and permeabilized in 0.2% Triton X-100 plus 1% normal goat serum (NGS). Cells 566 
were washed again in PBS+1% NGS, and incubated with TIAR antibody (1:2000; CST) 567 
for 1 hour at room temp in a humidified chamber. Cells were washed again PBS+1% 568 
NGS, and incubated with Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary 569 
Antibody, Alexa Fluor 488 (1:1000; Thermo Fisher) secondary antibody for 1 hour at 570 
room temp. Cover slips were washed with PBS before mounting with ProLong Diamond 571 
antifade (Thermo Fisher). 572 
Cell viability assays 573 
Cells were seeded at a density of 10,000 cells/well (100 µl per well) into 24-well 574 
plates and treated with 2.5 µM of either a PHAROH-specific ASO or scASO. Cells were 575 
grown for 96 h at 37°C. 20 µl of solution (CellTiter 96® AQueous One Solution Reagent, 576 
Promega) was added to the wells and incubated for 4 h at 37°C. Measurements of 577 
absorbance at 490 nm were performed using a SpectraMax i3 Multi-Mode Detection 578 
Platform (Molecular Devices). Background absorbance at 690 nm was subtracted. Cells 579 
were also trypsinized, pelleted, and manually counting using a hemocytometer. 580 
RNA antisense pulldown and mass spectrometry 581 
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 RNA antisense pulldown—Cells were lysed on a 10 cm plate in 1 mL IP lysis 582 
buffer (IPLB, 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 5% 583 
glycerol, supplemented with 100 U/mL SUPERase-IN and 1X Roche protease inhibitor 584 
cocktail) for 10 minutes, and lysate was centrifuged at 13,000xg for 10 minutes. Cell 585 
lysate was adjusted to 0.3 mg/mL (Bradford assay). 100 pmol of biotinylated oligo was 586 
added to 500 uL of lysate and incubated at room temperature for 1 hour with rotation. 587 
100 uL streptavidin Dynabeads were washed in IPLB, added to the lysate, and 588 
incubated for 30 minutes at room temperature with rotation. Beads were washed three 589 
times with 1 mL lysis buffer. For determining temperature for optimal elution, beads 590 
were then resuspended in 240 uL of 100 mM TEAB and aliquoted into eight PCR tubes. 591 
Temperature was set on a veriflex PCR block and incubated for 10 minutes. Beads 592 
were captured and TRIzol was added to the eluate and beads. Once optimal 593 
temperature is established, the beads were resuspended in 90 uL of 100 mM TEAB, 594 
and incubated at 40° C for 10 minutes. TRIzol was added to 30 uL of the eluate, another 595 
30 uL was kept for western blots, and the last 30 uL aliquot was sent directly for mass 596 
spectrometry.  597 
Tryptic digestion and iTRAQ labeling—Eluted samples were reduced and 598 
alkylated with 5 mM DTT and 10 mM iodoacetamide for 30 min at 55 °C, then digested 599 
overnight at 37 °C with 1 μg Lys-C (Promega, VA1170) and dried in vacuo. Peptides 600 
were then reconstituted in 50 μl of 0.5 M TEAB/70% ethanol and labeled with 4-plex 601 
iTRAQ reagent for 1 h at room temperature essentially as previously described (Ross et 602 
al., 2004). Labeled samples were then acidified to <pH 4 using formic acid, combined 603 
and concentrated in vacuo until ~10 μl remained. 604 
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Two-dimensional fractionation—Peptides were fractionated using a Pierce™ 605 
High pH Reversed-Phase Peptide Fractionation Kit (Thermo Scientific, 84868) 606 
according to the manufacturer’s instructions with slight modifications. Briefly, peptides 607 
were reconstituted in 150 μl of 0.1% TFA, loaded onto the spin column, and centrifuged 608 
at 3000 × g for 2 min. Column was washed with water, and then peptides were eluted 609 
with the following percentages of acetonitrile (ACN) in 0.1% triethylamine (TEA): 5%, 610 
7.5%, 10%, 12.5%, 15%, 20%, 30%, and 50%. Each of the 8 fractions was then 611 
separately injected into the mass spectrometer using capillary reverse-phase LC at low 612 
pH. 613 
Mass spectrometry—An Orbitrap Fusion Lumos mass spectrometer (Thermo 614 
Scientific), equipped with a nano-ion spray source was coupled to an EASY-nLC 1200 615 
system (Thermo Scientific). The LC system was configured with a self-pack PicoFrit™ 616 
75-μm analytical column with an 8-μm emitter (New Objective, Woburn, MA) packed to 617 
25 cm with ReproSil-Pur C18-AQ, 1.9 μM material (Dr. Maish GmbH). Mobile phase A 618 
consisted of 2% acetonitrile; 0.1% formic acid and mobile phase B consisted of 90% 619 
acetonitrile; 0.1% formic acid. Peptides were then separated using the following steps: 620 
at a flow rate of 200 nl/min: 2% B to 6% B over 1 min, 6% B to 30% B over 84 min, 30% 621 
B to 60% B over 9 min, 60% B to 90% B over 1 min, held at 90% B for 5 min, 90% B to 622 
50% B over 1 min and then flow rate was increased to 500 μl/min as 50% B was held for 623 
9 min. Eluted peptides were directly electrosprayed into the MS with the application of a 624 
distal 2.3 kV spray voltage and a capillary temperature of 300 °C. Full-scan mass 625 
spectra (Res = 60,000; 400–1600 m/z) were followed by MS/MS using the “Top Speed” 626 
method for selection. High-energy collisional dissociation (HCD) was used with the 627 
normalized collision energy set to 35 for fragmentation, the isolation width set to 1.2 and 628 
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a duration of 15 s was set for the dynamic exclusion with an exclusion mass width of 10 629 
ppm. We used monoisotopic precursor selection for charge states 2+ and greater, and 630 
all data were acquired in profile mode. 631 
Database searching 632 
Peaklist files were generated by Proteome Discoverer version 2.2.0.388 (Thermo 633 
Scientific). Protein identification was carried out using both Sequest HT (Eng et al., 634 
1994) and Mascot 2.5 (Perkins et al., 1999) against the UniProt mouse reference 635 
proteome (57,220 sequences; 26,386,881 residues). Carbamidomethylation of cysteine, 636 
iTRAQ4plex (K), and iTRAQ4plex (N-term) were set as fixed modifications, methionine 637 
oxidation, and deamidation (NQ) were set as variable modifications. Lys-C was used as 638 
a cleavage enzyme with one missed cleavage allowed. Mass tolerance was set at 20 639 
ppm for intact peptide mass and 0.3 Da for fragment ions. Search results were rescored 640 
to give a final 1% FDR using a randomized version of the same Uniprot mouse 641 
database, with two peptide sequence matches (PSMs) required. iTRAQ ratio 642 
calculations were performed using Unique and Razor peptide categories in Proteome 643 
Discoverer. 644 
RNA Electromobility shift assay 645 
 DNA template used for in vitro synthesis of RNA probes were from annealed 646 
oligos. A T7 RNA polymerase promoter sequence was added to allow for in vitro 647 
transcription using the MEGAscript T7 transcription kit (Thermo Fisher). RNA was end 648 
labelled at the 3’ end with biotin using the Pierce RNA 3’ End Biotinylation Kit (Thermo 649 
Fisher). RNA quantity was assayed by running an RNA 6000 Nano chip on a 2100 650 
Bioanalyzer. Six percent acrylamide gels (39:1 acrylamide:bis) (Bio-Rad) containing 0.5 651 
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X TBE were used for all EMSA experiments. Recombinant human TIAR (Proteintech) 652 
was added at indicated concentrations to the probe (~2 fmol) in 20 uL binding buffer, 653 
consisting of 10 mM HEPES (pH 7.3), 20 mM KCL, 1 mM Mg2Cl2, 1 mM DTT, 30 ng/uL 654 
BSA, 0.01% NP-40, and 5% glycerol. After incubation at room temperature for 30 655 
minutes, 10 uL of the samples were loaded and run for 1 hr at 100 V. The nucleic acids 656 
were then transferred onto a positively charged nylon membrane (Amersham Hybond-657 
N+) in 0.5 X TBE for 30 minutes at 40 mAh. Membranes were crosslinked using a 254 658 
nM bulb at 120 mJ/cm2 in a Stratalinker 1800. Detection of the biotinylated probe was 659 
done using the Chemiluminescent Nucleic Acid Detection Module Kit (Thermo Fisher 660 
89880). 661 
3’ UTR luciferase assay 662 
 The full length 3’ UTR of c-Myc was cloned into the pmirGLO Dual-Luciferase 663 
miRNA target expression vector (Promega). Luciferase activity was assayed in 664 
transfected cells using the Dual-Luciferase Reporter Assay (Promega). To evaluate the 665 
interaction between PHAROH, 3’ UTR of c-Myc, and TIAR, cells were transfected with 666 
the respective constructs using Lipofectamine 3000. Twenty-four hours later, firefly and 667 
Renilla luciferase activity was measured, and Renilla activity was used to normalize 668 
firefly activity. 669 
Single Molecule RNA FISH 670 
#1.5 round glass coverslips were prepared by acid-cleaning and layered with 671 
gelatin for 20 minutes, prior to seeding MEF feeder cells and ESCs. Cells were fixed for 672 
30 minutes in freshly-prepared 4% PFA (Electron Microscopy Sciences), diluted in D-673 
PBS without CaCl2 and MgCl2 (Gibco, Life Technologies) and passed through a 0.45 674 
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µm sterile filter. Fixed cells were dehydrated and rehydrated through an ethanol 675 
gradient (50% - 75% - 100% - 75% - 50%- PBS) prior to permeabilization for 5 minutes 676 
in 0.5% Triton X-100. Protease QS treatment was performed at a 1:8,000 dilution. 677 
QuantiGene ViewRNA (Affymetrix) probe hybridizations were performed at 40°C in a 678 
gravity convection incubator (Precision Scientific), and incubation time of the pre-679 
amplifier was extended to 2 hours. Nuclei were counter-stained with DAPI and 680 
coverslips mounted in Prolong Gold anti-face medium 681 
(www.spectorlab.labsites.cshl.edu/protocols). 682 
Coverslips were imaged on a DeltaVision Core system (Applied Precision), 683 
based on an inverted IX-71 microscope stand (Olympus) equipped with a 60x U-684 
PlanApo 1.40 NA oil immersion lens (Olympus). Images were captured at 1x1 binning 685 
using a CoolSNAP HQ CCD camera (Photometric) as z-stacks with a 0.2 µm spacing. 686 
Stage, shutter and exposure were controlled through SoftWorx (Applied Precision). 687 
Image deconvolution was performed in SoftWorx. 688 
A spinning-disc confocal system (UltraVIEW Vox; PerkinElmer) using a scanning 689 
unit (CSU-X1; Yokogawa Corporation of America) and a charge-coupled device camera 690 
(ORCA-R2; Hamamatsu Photonics) fitted to an inverted microscope (Nikon) equipped 691 
with a motorized piezoelectric stage (Applied Scientific Instrumentation). Image 692 
acquisition was performed using Volocity versions 5 and 6 (PerkinElmer). Routine 693 
imaging performed using Plan Apochromat 60 or 100× oil immersion objectives, NA 1.4. 694 
RNA sequencing and analysis 695 
Total RNA was isolated either directly from cryosections of the tumor tissue or 696 
from organotypic epithelial cultures using TRIzol according to the manufacturer’s 697 
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instructions. RNA quality was assayed by running an RNA 6000 Nano chip on a 2100 698 
Bioanalyzer. For high-throughput sequencing, RNA samples were required to have an 699 
RNA integrity number (RIN) 9 or above. TruSeq (Illumina) libraries for poly(A)+ RNA-700 
seq were prepared from 0.5–1mg RNA per sample. To ensure efficient cluster 701 
generation, an additional gel purification step of the libraries was applied. The libraries 702 
were multiplexed (12 libraries per lane) and sequenced single-end 75 bp on the 703 
NextSeq500 platform (Illumina), resulting in an average 40 Million reads per library. 704 
Analysis was performed in GalaxyProject. In brief, reads were first checked for quality 705 
using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), and a 706 
minimum Phred score of 30 was required. Reads were then mapped to the mouse 707 
mm10 genome using STAR (Dobin et al., 2013), and counts were generating using 708 
htseq-counts with the appropriate GENCODE M20 annotation. Deseq2  was then used 709 
to generate the list of differentially expressed genes (Love et al., 2014). Motif analysis 710 
was performed using HOMER (Heinz et al., 2010). 711 
Coding analysis 712 
 cDNA sequences of PHAROH and GAPDH were inputted into CPAT 713 
(http://lilab.research.bcm.edu/cpat/) or CPC 714 
(http://cpc.cbi.pku.edu.cn/programs/run_cpc.jsp) for analysis (Kong et al., 2007; L. 715 
Wang et al., 2013). PhyloCSF analysis was performed using the UCSC Genome 716 
Browser track hub 717 
(https://data.broadinstitute.org/compbio1/PhyloCSFtracks/trackHub/hub.DOC.html) (M. 718 
F. Lin et al., 2011). 719 
Plasmid construction 720 
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 eSpCas9(1.1) was purchased from Addgene (#71814). eSpCas9-2A-GFP was 721 
constructed by subcloning 2A-GFP from pSpCas9(BB)-2A-GFP (PX458) (Addgene 722 
#48138) into eSpCas9 using EcoRI sites. To construct eSpCas9-2A-mCherry, 2A-723 
mCherry was amplified from mCherry-Pol II (Zhao et al., 2011), and an internal BbsI site 724 
was silently mutated. The PCR product was then cloned into eSpCas9 using EcoRI 725 
sites. The PHAROH construct was amplified using Hepa1-6 cDNA as a template and 726 
cloned into pCMV6 using BamHI and FseI. Mutant PHAROH was constructed by 727 
amplifying tiled oligos and cloned into pCMV6 using BamHI and FseI. 728 
CRISPR/Cas9 genetic knockout 729 
To generate a genetic knockout of PHAROH, two sgRNAs targeting the promoter 730 
region were combined, creating a deletion including the TSS. Guide design was 731 
performed on Benchling (https://benchling.com) taking into account both off-target 732 
scores and on-target scores. The sgRNA targeting the gene body of PHAROH was 733 
cloned into a pSpCas9(BB)-2A-GFP vector (PX458, Addgene plasmid #48138) and the 734 
sgRNA targeting the upstream promoter region was cloned into a pSpCas9(BB)- 2A-735 
mCherry vector. Hepa1-6 were transfected with both plasmids using the 4D-736 
Nucleofector™ System (Lonza) using the EH-100 program in SF buffer. To select for 737 
cells expressing both gRNAs, GFP and mCherry double positive cells were sorted 48 738 
hours post transfection, as single cell deposition into 96-well plates using a FACS Aria 739 
(SORP) Cell Sorter (BD). Each single cell clone was propagated and analyzed by 740 
genomic PCR and qRT-PCR to select for homozygous knockout clones. Cells 741 
transfected with a sgRNA targeting Renilla luciferase were used as a negative control.  742 
Cell cycle analysis 743 
 33 
 Hoechst 33342 (Sigma) was added to cells at a final concentration of 5 μg/mL 744 
and incubated at 37° C for 1 hour. Cells were trypsinized and collected into a flow 745 
cytometry compatible tube. Profiles were analyzed using a FACS Aria (SORP) Cell 746 
Sorter (BD), gated according to DNA content and cell cycle phase, and sorted into 747 
Eppendorf tubes for subsequent RNA extraction and qRT-PCR analysis. 748 
Nucleofection 749 
For transfection of ASOs using nucleofection technology (Lonza), ESCs were 750 
harvested following soaking off of feeder cells for one hour, washed in D-PBS (Gibco, 751 
Life Technologies) and passed through a 70 µm nylon cell strainer (Corning). Cell count 752 
and viability was determined by trypan blue staining on a Countess automated cell 753 
counter (Life Technologies). For each reaction, 1x106 viable cells were resuspended in 754 
SF Cell Line Solution (Lonza), mixed with 2 µM control or 2 µM target-specific ASO and 755 
transferred to nucleocuvettes for nucleofection on a 4D-Nucleofector System (Lonza) 756 
using program code “EH-100”. For plasmid nucleofections, 10 ug of plasmid was used 757 
and nucleofected using program code “EH-100”. Cells were subsequently transferred 758 
onto gelatinized cell culture plates containing pre-warmed and supplemented growth 759 
medium. Growth medium was changed once after 16 hours. 760 
Colony Formation Assay 761 
200 Hepa1-6 cells were seeded in a 6-well plate. ASOs were added at the time 762 
of seeding at the indicated concentrations. Two weeks later, cells were fixed, stained 763 
with Giemsa, counted and photographed. 764 
2’-O-Methoxyethyl (MOE) antisense oligonucleotides and knockdown analysis 765 
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Synthesis and purification of all 2’-MOE modified oligonucleotides was performed 766 
as previously described (Meng et al. 2014) by Ionis Pharmaceuticals. These ASOs are 767 
20-mer oligonucleotides containing a phosphorothioate backbone, 2’-O-methoxyethyl 768 
modifications on the first and last five nucleotides and a stretch of ten DNA bases in the 769 
center. Constrained ethyl oligos are 16-mer oligonucleotides that contain modifications 770 
on the first and last 3 nucleotides and a stretch of ten DNA bases in the center.  771 
qRT-PCR 772 
To assess knockdown efficiency TRIzol-extracted RNA was treated with RNAse-773 
free DNAseI (Life Technologies) and subsequently reverse-transcribed into cDNA using 774 
TaqMan Reverse Transcription reagents and random hexamer oligonucleotides (Life 775 
Technologies). Real-time PCR reactions were prepared using Power SYBR Green 776 
Master Mix (Life Technologies) and performed on an ABI StepOnePlus Real-Time PCR 777 
system (Life Technologies) for 40 cycles of denaturation at 95°C for 15 seconds 778 
followed by annealing and extension at 60°C for 60 seconds. Primers were designed to 779 
anneal within an exon to detect both primary and processed transcripts. Primer 780 
specificity was monitored by melting curve analysis. For each sample, relative 781 
abundance was normalized to the housekeeping gene PPIB mRNA levels. 782 
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Figure 1. LncRNA screen to identify transcripts enriched in ESCs and 978 
dysregulated in cancer 979 
A. PCA plot of 10 RNA-seq libraries from mouse derived ESCs, and two from cell 980 
lines. Differentiation from ESCs to NPCs created the largest difference in 981 
variance, while there was minimal difference between isolated clones vs. cell 982 
lines. 983 
B. Workflow of the filtering process performed to obtain ESC enriched lncRNAs 984 
that are also dysregulated in cancer. Red indicates analysis performed in mouse 985 
and blue indicates human. 986 
C. LncRNA candidate expression across ENCODE tissue datasets show that 987 
lncRNAs are mostly not pan-expressed, but are rather tissue specific. Counts 988 
are scaled per row. 989 
D. LINC00862 is upregulated in both human cirrhotic liver and HCC tumor samples 990 
when compared to control patient liver tissue samples. 991 
**p < 0.01; ***p < 0.005; Student’s t-test. 992 
E. LINC00862 is upregulated in various human HCC cell lines. 993 
 994 
Figure 2. PHAROH lncRNA is highly expressed in ESCs, embryonic liver, models 995 
of hepatocarcinogenesis, and HCC cell lines  996 
A. 5’ 3’ RACE reveals two isoforms for PHAROH, which have exons 3 and 4 in 997 
common. PHAROH is an intergenic lncRNA where the nearest upstream gene 998 
is Zfp218 (51 kb away), and downstream is Nr5a2 (151 kb away). RNA-seq 999 
tracks of ESC (red) and Hepa1-6 (blue) cells show cell-type specific isoform 1000 
expression of PHAROH. 1001 
B. PHAROH is highly expressed in embryonic liver in E14 and E18 mice, but not 1002 
adult liver (**p < 0.01; ***p < 0.005; Student’s t-test). 1003 
C. A DEN model of hepatocarcinogenesis shows high upregulation of PHAROH in 1004 
the liver and HCC tumor nodules (gray bar) in DEN treated mice (**p < 0.01; 1005 
***p < 0.005; Student’s t-test.). 1006 
D. PHAROH is upregulated in HCC cell lines (Hepa1-6, and Hepa1c1c7) 1007 
compared to normal mouse hepatocytes (AML12) (***p < 0.005; Student’s t-1008 
test). 1009 
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E. Single molecule RNA-FISH of PHAROH in ESCs shows nuclear localization and 1010 
an average of 3-5 foci per cell. In Hepa1-6 cells, PHAROH shows 25 foci per 1011 
cell, distributed evenly between the nucleus and cytoplasm (n=75 cells for each 1012 
sample). Ppib is used as a housekeeping protein coding gene control. 1013 
F. Quantitation of panel PHAROH foci in panel E in HepA1-6 cells 1014 
G. Cellular fractionation of Hepa1-6 cells shows equal distribution of PHAROH in 1015 
the cytoplasm and nucleus, where it also binds to chromatin. Gapdh is 1016 
predominantly cytoplasmic, and MALAT1 is bound to chromatin. 1017 
 1018 
 1019 
Figure 3. Depletion of PHAROH results in a proliferation defect 1020 
A. Four isolated clones all have a comparable deletion of 788 bp. The wildtype 1021 
band is ~1.8 kb. 1022 
B. qRT-PCR of PHAROH knockout clones show a >80% reduction in PHAROH 1023 
levels (***p < 0.005; Student’s t-test). 1024 
C. Aggregated doubling time of clones shows knockout of PHAROH increases 1025 
doubling time from 14.8h to 18.6h. Addition of PHAROH back into knockouts 1026 
rescues this defect (***p < 0.005; Student’s t-test). 1027 
D. Manual cell counting shows proliferation defect in PHAROH knockout cells that 1028 
is rescued by ectopic expression of PHAROH (*p < 0.05; Student’s t-test). 1029 
E. Migration distance for PHAROH knockout clones is decreased by 50% (**p < 1030 
0.01; Student’s t-test). 1031 
F. 50% Knockdown of PHAROH can be achieved using both ASO7 and ASO15 at 1032 
24h (***p < 0.005; Student’s t-test). 1033 
G. Colony formation assay of Hepa1-6 cells that are treated with scrambled or 1034 
PHAROH targeting ASOs. After seeding 200 cells and two weeks of growth, a 1035 
50% reduction in relative colony number is observed (**p < 0.01; Student’s t-1036 
test). 1037 
 1038 
Figure 4. Gene expression analysis of PHAROH knockout cells reveals a link to 1039 
MYC 1040 
A. GO term analysis of differentially expressed genes shows enrichment of cell 1041 
 46 
proliferation and migration genes 1042 
B. qRT-PCR of Myc mRNA levels indicate that Myc transcript does not appreciably 1043 
change when PHAROH is knocked out. 1044 
C. Western blot analysis of MYC protein shows downregulation of protein levels in 1045 
PHAROH knockout cells. β-ACTIN is used as a loading control. 1046 
D. qRT-PCR of genes downstream of Myc shows a statistically significant 1047 
decrease in expression (*p < 0.05; **p < 0.01; Student’s t-test). 1048 
 1049 
Figure 5. RAP-MS identifies TIAR as a major interactor of PHAROH 1050 
A. Five different biotinylated oligos antisense to PHAROH were screened for 1051 
pulldown efficiency. Oligos 2-5 can pull down PHAROH at ~80% efficiency or 1052 
greater 1053 
B. PHAROH can be eluted at a specific temperature. Maximum elution is reached 1054 
at 40° C. 1055 
C. iTRAQ results using two different oligos targeting PHAROH compared to PPIB 1056 
reveal nucleolysin TIAR as the top hit. 1057 
D. TIAR is pulled down by PHAROH oligos, and is specifically eluted at 40° C, but 1058 
not by PPIB oligos. 1059 
E. TIAR can be pulled down using additional oligos and in two different cell lines. 1060 
RNase A treatment of the protein lysate diminishes TIAR binding to PHAROH, 1061 
indicating that the interaction is RNA-dependent. 1062 
F. Immunoprecipitation of TIAR enriches for PHAROH transcript, when compared 1063 
to IgG and PPIB control (***p < 0.005; Student’s t-test). 1064 
 1065 
Figure 6. TIAR binds to the 5’ end of PHAROH 1066 
A. Sequence analysis of PHAROH with published TIAR binding motifs shows a 1067 
preference for the 5’ end of PHAROH. 1068 
B. Schematic of the conserved hairpin of PHAROH that contains four potential 1069 
TIAR binding sites indicated in the red boxes. Mutations created within the 1070 
PHAROH hairpin are indicated in red asterisks. 1071 
C. RNA EMSA of the 71-nt PHAROH hairpin with human recombinant TIAR shows 1072 
three sequential shifts as TIAR concentration increases. 1073 
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D. Densitometry analysis of the free unbound probe estimates the dissociation 1074 
constant of TIAR as ~2 nM. 1075 
E. TIAR/PHAROH binding is specific as a supershift is created when adding 1076 
antibody against TIAR, and the interaction can be competed out using 20x 1077 
unlabeled RNA. RNA EMSA of the mutant hairpins reveals decreasing affinity 1078 
for TIAR. Mutants were made in a cumulative 5’ to 3’ fashion. M1 shows high 1079 
signal of single and double occupancy forms, and m2 has reduced signal 1080 
overall. When all four sites are mutated, binding is nearly abolished. 1081 
 1082 
Figure 7. Loss of PHAROH releases TIAR, which inhibits Myc translation 1083 
A. RNA EMSA of the 53-nt Myc 3’ UTR fragment shows that TIAR has three 1084 
potential binding sites, but prefers a single binding event (note arrows) 1085 
B. Knockdown of PHAROH reduces MYC protein levels, but not TIAR levels, even 1086 
though MYC is expressed 3-fold higher than PHAROH. 1087 
C. Wildtype PHAROH hairpin is able to compete out the MYC-TIAR interaction, but 1088 
the mutated hairpin is not as effective in competing with the Myc-TIAR 1089 
interaction. 1090 
D. Luciferase activity is increased with the addition of PHAROH but not with 1091 
m4PHAROH (**p < 0.01; Student’s t-test). 1092 
E. Overexpression of PHAROH increases MYC protein expression, but 1093 
overexpression of m4PHAROH does not change MYC levels appreciably.  1094 
 1095 
  1096 
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Figure 1-figure supplement 1. 1097 
A. LncRNA screen identifies candidates with varying levels of expression in ESCs. 1098 
B. LINC00862 is altered in 13% of all HCC patient cases according to TCGA data. 1099 
C. Gm19705 gene locus on chromosome 1 shows that the order of the genes is 1100 
conserved between mouse and human, but the order is reversed, suggesting a 1101 
reversal event occurrence. 1102 
D. Weighted gene correlation network analysis of Gm19705 places it in a module 1103 
with cell cycle genes and proliferation genes, such as Brca1/2, and Mki67. 1104 
E. GO term analysis of the module containing Gm19705 shows enrichment of 1105 
genes related to cell cycle, mitosis, and DNA replication. 1106 
F. Re-analysis of single cell data of adult liver (Tabula Muris et al., 2018) reveals 1107 
expression of Gm19705 is highly enriched in hepatocytes, but only a subset of 1108 
the cells. 1109 
 1110 
Figure 2-figure supplement 2. 1111 
A. CPC and CPAT coding potential analysis for PHAROH and Gapdh. 1112 
B. PhyloCSF tracks showing low coding potential for the PHAROH locus 1113 
C. PHAROH is expressed in fetal liver, but not in the blood. 1114 
D. Sham hepatectomy (SH) or partial hepatectomy (PH) of the liver, a model of liver 1115 
regeneration, shows upregulation of PHAROH during time points of concerted 1116 
cell division. 1117 
*p < 0.05; **p < 0.01; ***p < 0.005; Student’s t-test.  1118 
E. HepA1-6 cells were stained with Hoechst 33258 and sorted according to their cell 1119 
cycle phase. qRT-PCR analysis shows that PHAROH does not cycle with the cell 1120 
cycle, unlike Ccnb1 and Ccne1. 1121 
F. qRT-PCR of each annotated exon spanning the current Gencode M20 1122 
annotation. Exons 1-4, which are numbered similarly as Figure 2A, are confirmed 1123 
RACE exons. Isoform with exons 1, 3, and 4 is ESC specific, and the isoform 1124 
with exons 2-4 is HCC specific. Exons A, B, C, D, and E are currently annotated 1125 
exons, but not identifiable via RACE. 1126 
G. XIST, FIRRE, and NEAT1 serve as additional controls for the cellular 1127 
fractionation. 1128 
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H. Calculated RNA half-life based upon α-amanitin treated cells. PHAROH has a 1129 
half-life of 10.8h, longer than that of XIST and MALAT1. 1130 
 1131 
Figure 3-figure supplement 3. 1132 
A. FACS for double GFP+/mCherry+ cells shows an 85.1% nucleofection efficiency 1133 
for both plasmids. 1134 
B. Knockdown of PHAROH using nucleofection of 2 μM ASO is effective over 96h. 1135 
C. MTS assay for proliferation 96h after nucleofection. MTS absorbance is reduced 1136 
by 50% in ASO treated samples targeting PHAROH and Eg5. 1137 
D. Reduction of colony formation number is dose dependent. 1138 
 1139 
Figure 4-figure supplement 4. 1140 
A. Principal component analysis of two sgRenilla negative control clones and two 1141 
PHAROH knockout clones. Deletion of PHAROH is well separated by PC1. 1142 
B. Euclidean distance plot indicating that the negative control clones and PHAROH 1143 
knockout clones cluster independently. 1144 
C. Motif analysis of promoter region of differentially expressed genes. MYC motif is 1145 
enriched 1.24 fold over background sequences. 1146 
D. Immunofluorescence of MYC in PHAROH knockout clones shows absence of 1147 
MYC signal in a majority of cells. Scale bar = 50 μm. 1148 
E. Quantification of western blot in Figure 4C. 1149 
 1150 
Figure 5-figure supplement 5. 1151 
A. The amount of PHAROH RNA remaining on the beads after thermal elution is 1152 
inverse to that of the eluate. 1153 
B. Off-target pulldown of Ppib using PHAROH oligos is low. 1154 
C. An oligo designed against Ppib can pull the RNA down at ~65% efficiency, and 1155 
does not pull down PHAROH or 18S. 1156 
D. Ppib can also be eluted via a temperature gradient, and is optimally released at 1157 
40° C. 1158 
 1159 
Figure 6-figure supplement 6. 1160 
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A. Mapping the top seven binding sites to predicted structures (top three shown 1161 
here), reveals a conserved hairpin on the majority of predicted structures. 1162 
B. Profile analysis of the RNA EMSA gel in Fig. 6C, showing the shift in intensity. 1163 
C. Binding of TIAR to m2 and m3 are similar, possibly due to the mutation of a 1164 
weaker binding site does not greatly impact overall binding. 1165 
 1166 
Figure 7-figure supplement 7. 1167 
A. Of the two TIAR binding sites on MYC’s 3’ UTR, only one maps to the mouse 1168 
genome. 1169 
B. Potential TIAR binding sites on the mouse Myc 3’ UTR highlighted in red. 1170 
C. Knockdown of PHAROH does not change Myc mRNA levels, suggesting that 1171 
PHAROH acts at a post-transcriptional level. 1172 
D. Addition of PHAROH to a luciferase construct with a Myc 3’ UTR increases 1173 
luciferase activity in a dose dependent manner. 1174 
E. MYC RNA levels do not change when PHAROH or TIAR are overexpressed. 1175 
F. IF microscopy of TIAR showing predominantly nuclear localization. Scale bar = 1176 
25 μm 1177 
G. Kaplan-Meier survival plot of patients with low and high TIAR expression. 1178 
  1179 
 51 
Table 1 1180 
Gene Name Sequence Homology Synteny Human Homologue 
Platr15 - + LOC284798 
4930444M15Rik 64.4% of bases, 99.9% of span + In TUSC8 region 
5430416N02Rik 16.6% of bases, 100.0% of span + Thap9-AS1 
Platr6 45.2% of bases, 85.5% of span + LINC01010 
6720427I07Rik 94.3% of bases, 100.0% of span + LINC02603 
B830012L14Rik 57.4% of bases, 83.8% of span + Meg8 (GM26945) 
C330004P14Rik - + LINC01625 
Gm38509 22.9% of bases, 84.4% of span + LINC01206 
A330094K24Rik 54.7% of bases, 100.0% of span + C18orf25 (PCG) 
Bvht 53.2% of bases, 100.0% of span + Carmn 
Dancr 48.2% of bases, 49.0% of span + Dancr 
2900041M22Rik 50.2% of bases, 60.5% of span + LINC01973 
Dleu2 72.8% of bases, 100.0% of span + Dleu2 
E130202H07Rik 61.7% of bases, 65.2% of span  Tusc8 
Epb41l4aos 69.0% of bases, 100.0% of span + Epb41l4a-AS1 
Firre 7.0% of bases, 14.5% of span + Firre 
Gm20939 - + LINC00470 
Gas5 71.3% of bases, 97.7% of span + Gas5 
Gm12688 92.6% of bases, 100.0% of span + FOXD3-AS1 
Gm47599 21.6% of bases, 85.0% of span + Socs2-AS1 
Gm19705 27.6% of bases, 47.8% of span + LINC00862 
Gm20703 79.2% of bases, 100.0% of span + GAPLINC 
Gm26763 3.6% of bases, 3.8% of span + Smarca5-AS1 
Gm26945 65.4% of bases, 67.8% of span + Meg8 
AC129328.1 - + LINC01340, 
Gm28373 44.6% of bases, 83.5% of span + Itpk1-AS1 
Gm31693 12.7% of bases, 24.9% of span + LINC00578 
Mir124a-1hg 91.7% of bases, 100.0% of span + LINC00599 
Mir142hg 74.5% of bases, 100.0% of span + TSPOAP1-AS1 
Mir17hg 74.7% of bases, 100.0% of span + Mir17Hg 
Neat1 37.5% of bases, 100.0% of span + NEAT1 
Platr12 16.2% of bases, 33.7% of span + GPR1-AS 
Rbakdn 96.4% of bases, 99.1% of span + Rbakdn 
Snhg1 73.3% of bases, 89.2% of span + Snhg1 
Snhg14 4.5% of bases, 5.4% of span + Snhg14 
D5Ertd605e - + Pan3-AS1 
Snhg18 83.3% of bases, 100.0% of span + Snhg18 
Snhg5 67.8% of bases, 81.6% of span + Snhg5 
Sptbn5 78.8% of bases, 100.0% of span + Sptbn5 
Xist 70.1% of bases, 100.0% of span + Xist 
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Table 2 1182 











































Ke┞ ResouヴIes TaHle ヱ 





































Cell liﾐe ふMus 
ﾏusculusぶ 
ABヲ.ヲ ふESCsぶ Beヴgﾏaﾐﾐ et al., 
ヲヰヱヵ 
 Cell liﾐe 
ﾏaiﾐtaiﾐed iﾐ D. 
L. SpeItoヴ LaH 
Cell liﾐe ふMus 
ﾏusculusぶ 
NPC Beヴgﾏaﾐﾐ et al., 
ヲヰヱヵ 
 Cell liﾐe 
ﾏaiﾐtaiﾐed iﾐ D. 
L. SpeItoヴ LaH 
Cell liﾐe ふMus 
ﾏusculusぶ 
Hepaヱ-ヶ ATCC Cat# CRL-ヱΒンヰ Cell liﾐe 
ﾏaiﾐtaiﾐed iﾐ D. 
L. SpeItoヴ LaH 
Cell liﾐe ふMus 
ﾏusculusぶ 
HepaヱIヱIΑ ATCC Cat# CRL-ヲヰヲヶ Cell liﾐe 
ﾏaiﾐtaiﾐed iﾐ D. 
L. SpeItoヴ LaH 
Cell liﾐe ふMus 
ﾏusculusぶ 
AMLヱヲ ATCC Cat# CRL-ヲヲヵヴ Cell liﾐe 
ﾏaiﾐtaiﾐed iﾐ D. 
L. SpeItoヴ LaH 




Cat# GSC-ヶヶヰヱG Iヴヴadiated 
feedeヴ MEFs 
Cell liﾐe ふHoﾏo 
sapieﾐsぶ 
SNU-ヱΒヲ ATCC Cat# CRL-ヲヲンヵ Cell liﾐe 
ﾏaiﾐtaiﾐed iﾐ D. 
L. SpeItoヴ LaH 
Cell liﾐe ふHoﾏo 
sapieﾐsぶ 
Huhヱ N/A Geﾐeヴous gift 
fヴoﾏ SIott Lo┘e 
ふMSKCCぶ 
Cell liﾐe ふHoﾏo 
sapieﾐsぶ 
HuhΑ N/A Geﾐeヴous gift 
fヴoﾏ SIott Lo┘e 
ふMSKCCぶ 
Cell liﾐe ふHoﾏo 
sapieﾐsぶ 
JHHヲ N/A  RNA gifted fヴoﾏ 
SIott Lo┘e 
ふMSKCCぶ 
Cell liﾐe ふHoﾏo 
sapieﾐsぶ 
SNU-ンΒΑ ATCC Cat# CRL-ヲヲンΑ Geﾐeヴous gift 
fヴoﾏ SIott Lo┘e 
ふMSKCCぶ 
Cell liﾐe ふHoﾏo HepンB ATCC Cat# HB-Βヰヶヴ Geﾐeヴous gift 
sapieﾐsぶ fヴoﾏ SIott Lo┘e 
ふMSKCCぶ 
Cell liﾐe ふHoﾏo 
sapieﾐsぶ 
Ale┝ ATCC Cat# CRL-Βヰヲヴ RNA gifted fヴoﾏ 
SIott Lo┘e 
ふMSKCCぶ 
Cell liﾐe ふHoﾏo 
sapieﾐsぶ 
HepGヲ ATCC Cat# HB-Βヰヶヵ Geﾐeヴous gift 
fヴoﾏ SIott Lo┘e 
ふMSKCCぶ 
Cell liﾐe ふHoﾏo 
sapieﾐsぶ 
LiΑ N/A  RNA gifted fヴoﾏ 
SIott Lo┘e 
ふMSKCCぶ 
Cell liﾐe ふHoﾏo 
sapieﾐsぶ 
THLE-ヲ ATCC Cat# CRL-ヲΑヰヶ Cell liﾐe 
ﾏaiﾐtaiﾐed iﾐ D. 

















AﾐtiHod┞ β-AItiﾐ, ふﾏouse 
ﾏoﾐoIloﾐalぶ 



























Ale┝a Fluoヴ ヴΒΒ 




AﾐtiHod┞ RaHHit IgG 
Isot┞pe Coﾐtヴol 























This stud┞ N/A  
ReIoﾏHiﾐaﾐt 
DNA ヴeageﾐt 

































Chaﾐg et al., 
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Chaﾐg et al., 
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SeケueﾐIe-Hased E┝oﾐ A Re┗ This stud┞ PHAROH ケRT- GAATTTGCTCAG
ヴeageﾐt PCR GGGCTCCA 
SeケueﾐIe-Hased 
ヴeageﾐt 





























































































































































































































CoﾏﾏeヴIial DNase I, Life Cat# ヱΒヰヶΒ  









Theヴﾏo Fisheヴ Cat# ヴンヰヴヱンヴ
CoﾏﾏeヴIial 
assa┞ oヴ kit 
SF Cell Liﾐe ヴD-
NuIleofeItoヴ X 
Kit L 
Loﾐza Cat# VヴXC-ヲヰヲヴ  
CoﾏﾏeヴIial 
assa┞ oヴ kit 
Vie┘ ISH Cell 
Assa┞ Kit 
Aff┞ﾏetヴi┝ Cat# QVCヰヰヰヱ  
CoﾏﾏeヴIial 
assa┞ oヴ kit 
MEGAsIヴipt™ TΑ 
TヴaﾐsIヴiptioﾐ Kit 
Theヴﾏo Fisheヴ AMヱンンン  
CoﾏﾏeヴIial 
assa┞ oヴ kit 
PieヴIe™ RNA ン' 
Eﾐd 
Biotiﾐ┞latioﾐ Kit 
Theヴﾏo Fisheヴ Cat# ヲヰヱヶヰ  
CoﾏﾏeヴIial 
assa┞ oヴ kit 
LightShift™ 
CheﾏiluﾏiﾐesIe
ﾐt RNA EMSA 
Kit 
Theヴﾏo Fisheヴ Cat# ヲヰヱヵΒ
CoﾏﾏeヴIial 






Cat# ヲンヲヲΑ  
CoﾏﾏeヴIial 






Pヴoﾏega Cat# GンヵΒヲ  
CoﾏﾏeヴIial 
assa┞ oヴ kit 
SMARTeヴ RACE 
ヵ’/ン’ Kit 
Takaヴa Cat# ヶンヴΒヵΒ  
CoﾏﾏeヴIial 





Pヴoﾏega Cat# EヱΓヶヰ  
CoﾏﾏeヴIial 
assa┞ oヴ kit 
DNeas┞ Blood 
aﾐd Tissue kit 































































































































Cat# Dヱンヰヶ ヱ ug/ﾏL 
CheﾏiIal 
Ioﾏpouﾐd, dヴug 
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Figure 6 - figure supplement 6
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